**Specifications TableSubject***Biology***Specific subject area***Genetics***Type of data***Table and figure***How data were acquired***MALDI/TOF mass spectrometry using the Sequenom MassARRAY 4.0 platform (Agena Bioscience™)***Data format***Raw and analyzed data***Parameters for data collection***Whole blood (5* *ml) was drawn to a plastic vial (Vacutainer^Ⓡ^) containing 0.5* *M EDTA (рН=8.0). Genomic DNA was isolated by the standard phenol-chloroform method. DNA samples were first checked for quality (concentration 10--15* *ng/mL, purity А260/А280=1.7--2.0) and then used for genotyping. About 5% of blind replicate samples were used for genotyping quality control; the repeatability test indicated a 100% concordance rate.***Description of data collection***The quality of isolated DNA was checked by the Nanodrop-2000 spectrophotometer. Genotyping was performed on the Sequenom MassARRAY^Ⓡ^ iPLEX platform using the MALDI-TOF (matrix-assisted laser desorption/ ionization time-of-flight) mass spectrometry. Assay Design Suite 1.0 was used to design a multiplex genotyping assay* (<http://agenabio.com/assay-design-suite-10-software>)*.***Data source location***Belgorod, Russia***Data accessibility***The data is available with this article*

**Value of the data**•The frequencies of alleles and genotypes of rs1799750 *MMP1*, rs3918242 and rs17576 *MMP9* in Russian patients with POAG, EH, and PU are presented separately for the entire cohort, male and female participants.•The polymorphisms rs1799750 *MMP1*, rs3918242 and rs17576 *MMP9* may be associated with POAG, EH, and PU.•The data on the allele and genotype frequencies of the *MMP* genes can be used for meta-analyses of genetic studies on POAG, EH, and PU.•The presented data of the *MMP* genes polymorphisms can serve as a reference for population and genetic association studies of the common disorders.

1. Data description {#sec0001}
===================

The dataset contains the raw data (supplementary Table), frequencies of alleles and genotypes ([Table 1](#tbl0001){ref-type="table"}) for three SNPs of two *MMP* genes (rs1799750 *MMP1*, rs3918242 and rs17576 *MMP9*) in Russian patients diagnosed with POAG, EH, and PU. These polymorphisms were previously reported for their association with POAG, EH, and PU ([Table 2](#tbl0002){ref-type="table"}) [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044], [@bib0045]. The studied SNPs manifest the regulatory potential ([Table 3](#tbl0003){ref-type="table"}), which is evidenced by several eQTLs ([Table 4](#tbl0004){ref-type="table"}) and splicing QTLs ([Table 5](#tbl0005){ref-type="table"}). The allele and genotype frequencies are provided separately for the whole study cohort, females, and males, respectively. No significant differences in the frequencies of alleles and genotypes were found between the male and female participants for each of the studied diseases.Table 1The frequencies of alleles and genotypes for SNPs rs1799750 *MMP1*, rs3918242 and rs17576 *MMP9* in Russian patients with POАG, EH, and PU.Table 1DiseasesSNP genotype or alleleAllMaleFemalenfrequencynfrequencynfrequencyrs1799750POAG1G1G1520.2836730.2968790.27241G2G2670.49811310.53251360.46902G2G1170.2183420.1707750.25861G5710.53272770.56302940.50692G5010.46732150.43702860.4931rs3918242СС3850.71831750.71142100.7241СТ1330.2482650.2642680.2345ТТ180.033560.0244120.0414С9030.84244150.84354880.8414Т1690.1576770.1565920.1586rs17576AA2050.38251100.4472950.3276GA2600.48511080.43901520.5241GG710.1324280.1138430.1483A6700.62503280.66673420.5897G4020.37501640.33332380.4103EHrs17997501G1G1690.2721650.24811040.28971G2G3090.49761400.53341690.47072G2G1430.2303570.2175860.23961G6470.52092700.51533770.52512G5950.47912540.48473410.4749rs3918242СС4440.71501890.72142550.7103СТ1490.2399640.2443850.2368ТТ280.045190.0343190.0529С10370.83494420.84355950.8287Т2050.1651820.15651230.1713rs17576AA2290.36881000.38171290.3593GA3110.50081310.50001800.5014GG810.1304310.1183500.1393A7690.61923310.63174380.6101G4730.38081930.36832800.3899РUrs17997501G1G1210.3033450.2394760.36021G2G1950.4887980.5212970.45972G2G830.2080450.2394380.18011G4370.54761880.50002490.59012G3610.45241880.50001730.4099rs3918242СС2770.69421290.68621480.7014СТ1150.2883580.3085570.2701ТТ70.017510.005360.0285С6690.83833160.84043530.8365Т1290.1617600.1596690.1635rs17576AA1420.3559690.3670730.3460GA1840.4612830.44151010.4787GG730.1829360.1915370.1753A4680.58652210.58782470.5853G3300.41351550.41221750.4147[^1]Table 2The literature data about associations of the studied polymorphisms of the *ММР* genes with POАG, PU and some digestive diseases (gastric and esophageal cancer), EH and IS with EH.Table 2SNPGeneNumber of publications in PubMed/PubMed CentralPhenotypeAssociation (significance) (associated allele)Referencers1799750*MMP1*70/119POAGOR = 1.64, р = 0.01[@bib0001]POAGOR = 1.64, *p* = 0.002[@bib0002]POAGOR = 1.34, р = 0,017 (2 G)[@bib0003]POAGOR = 2.04, р\<0,001 (2 G)[@bib0004]POAGOR = 1.35, *p* = 0.017 (2 G)[@bib0005]POAG*p*\>0.05[@bib0006]peptic ulcerOR = 3.46, *p* = 0.03 (1 G/1 G)[@bib0007]gastric cancerOR = 3.34, р = 0.016 (2 G/2 G)[@bib0008]gastric cancerOR = 1.05, р = 0.013 (2 G)[@bib0009]IS with hypertensionOR = 1.54, *p* = 0.005 (2 G)[@bib0010]IS with hypertensionOR\>1; *p*\<0.05 (2 G)[@bib0011]IS with hypertension*p*\>0.05[@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017]essential hypertension in menOR = 2.58; р = 0.04 (together with rs11568818, rs1320632, rs11225395)[@bib0018]essential hypertension in women*p*\>0.05[@bib0019]rs3918242*MMP9*106/127POAGOR = 1.63; р = 0.002 (Т)[@bib0020]POAGOR = 1.55, *p* = 0.012 (T)[@bib0005]POAGOR = 1.46, *p* = 0.032 (CT+TT)[@bib0021]POAG*p*\>0.05\[[@bib0001],[@bib0004],[@bib0022]\]peptic ulcer*p*\>0.05[@bib0007]gastric cancerOR = 2.60; р\<0.05 (together with rs17576 and rs17577)[@bib0023]esophageal cancerOR = 2.71; р = 0.02 (СС)[@bib0024]gastric cancer*p*\>0.05[@bib0025]IS with hypertensionOR = 2,76; р = 0.003 (ТT)[@bib0026]IS with hypertensionOR = 1,73; р\<0,05 (Т)[@bib0027]IS with hypertensionOR = 2,20; р\<0,05 (ТТ)[@bib0028]IS with hypertensionOR = 2,08; р = 0,016 (Т)[@bib0029]IS with hypertensionOR\<1; р = 0.001 (CC)[@bib0030]IS with hypertensionOR\>1; р = 0.009 (T)[@bib0031]IS with hypertensionOR = 5,53; р = 0,001 (СС)[@bib0032]IS with hypertensionOR = 1.43; р = 0.001 (Т)[@bib0033]IS with hypertensionOR = 5.47; р\<0.05 (TТ)[@bib0034]IS with hypertensionOR = 1.27; р = 0.01 (T)[@bib0012]IS with hypertension*p*\>0.05[@bib0035]essential hypertensionOR = 1.30; р = 0.002[@bib0036]isolated systolic hypertensionOR\>1; р = 0,009 (T)[@bib0037]left ventricular hypertrophy in hypertensive patientsOR\>1; р = 0,0015 (together with rs2234681 and rs17576)[@bib0038]hypertension of pregnancyOR\<1; р = 0,007 (СС)[@bib0039]essential hypertension in childrenOR\>1; р\<0.05 (ТТ)[@bib0040]essential hypertension*p*\>0.05[@bib0041]rs17576*MMP9*78/97POAGOR = 1.96; р = 0.0005 (AG)[@bib0020]POAGOR = 0.66; *p* = 0.03 (A)[@bib0021]POAGOR = 1.53; *p* = 0.034 (GG)[@bib0042]POAG in menOR = 0.56; р = 0,003 (together with rs2250889)[@bib0043]POAGOR = 2.34; *p* = 0.01 (GG)[@bib0004]POAG*p*\>0.05[@bib0006]peptic ulcerOR = 0.49; *p* = 0.007 (AA)[@bib0007]gastric cancerOR = 4.34; р\<0.05 (Q)[@bib0023]gastric cancer*p*\>0.05[@bib0044]IS with hypertensionOR = 0,91; р  = 0,04 (GG)[@bib0045]IS with hypertension*p*\>0.05\[[@bib0015],[@bib0026],[@bib0029],[@bib0030],[@bib0031]\]left ventricular hypertrophy in hypertensive patientsOR\>1; р = 0,0015 (together with rs2234681 and rs3918242)[@bib0038]essential hypertensionOR\>1; р\<0.05 (АА)[@bib0041]isolated systolic hypertension*p*\>0.05[@bib0037][^2]Table 3Regulatory effects of the 3 SNPs of the *MMP* genes (HaploReg, v4.1, update 05.11.2015) (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>).Table 3![](fx1.gif)Table 4The cis-eQTL values of the 3 SNPs of the *MMP* genes. (according to Genotype-Tissue Expression (GTEx) (<http://www.gtexportal.org/>)).Table 4ChrSNPReference alleleAlternative alleleGene expressionEffect Size (β)P-ValueTissue11rs1799750TCT*MMP1*−0.669.6E-84Cells - Cultured fibroblasts*MMP1*−0.521.3E-25Thyroid*MMP1*−0.421.9E-25Lung*MMP1*−0.585.8E-23Heart - Atrial Appendage*MMP1*−0.450.0000000000000000017Adipose - Visceral (Omentum)*MMP1*−0.460.0000000000000066Heart - Left Ventricle*MMP1*−0.360.000000000022Nerve - Tibial*MMP1*−0.320.000000013Esophagus - Muscularis*MMP1*−0.350.000000015Artery - Aorta*MMP1*−0.280.000000024Adipose - Subcutaneous*MMP1*−0.220.00000038Artery - Tibial*MMP10*−0.190.0000025Lung*MMP1*−0.30.0000028Esophagus - Gastroesophageal Junction*MMP1*−0.280.0000075Breast - Mammary Tissue*WTAPP1*−0.150.00004Testis20rs3918242CT*SLC12A5*0.610.0000000000000000059Lung*SLC12A5*0.80.0000000000000016Adipose - Visceral (Omentum)*SLC12A5*0.60.000000000045Adipose - Subcutaneous*SLC12A5*0.690.000000045Breast - Mammary Tissue*SLC12A5*0.630.000000082Artery - Aorta*SLC12A5*0.780.00000018Spleen*SLC12A5*−0.610.00000019Adrenal Gland*SNX21*0.210.00000099Muscle - Skeletal*SLC12A5*0.450.0000029Thyroid*SLC12A5*0.430.0000037Nerve - Tibial*SLC12A5*0.430.0000038Uterus*SLC12A5*0.410.0000053Skin - Sun Exposed (Lower leg)*SLC12A5*0.480.00001Skin - Not Sun Exposed (Suprapubic)*PLTP*−0.250.000028Nerve - Tibial20rs17576AG*SLC12A5*−0.570.0000000000043Adrenal Gland*PLTP*−0.260.00000000033Lung*PLTP*−0.320.000000026Heart - Left Ventricle*PLTP*−0.240.000000034Nerve - Tibial*PLTP*−0.20.00000021Adipose - Subcutaneous*NEURL2*−0.30.00000026Adipose - Visceral (Omentum)*PLTP*−0.20.00000046Thyroid*PLTP*−0.190.00000055Artery - Tibial*PLTP*−0.370.00000066Adrenal Gland*NEURL2*−0.240.0000015Adipose - Subcutaneous*PLTP*−0.250.000002Artery - Aorta*NEURL2*−0.310.0000021Artery - Aorta*PLTP*−0.180.0000024Adipose - Visceral (Omentum)*PLTP*−0.30.0000025Colon - Sigmoid*PLTP*−0.220.0000033Brain - Frontal Cortex (BA9)*PCIF1*0.350.0000041Adrenal Gland*ZSWIM1*−0.260.0000068Adipose - Visceral (Omentum)*RP3--337O18.9*−0.220.0000076Lung*PLTP*−0.320.0000091Pituitary*SNX21*0.140.000012Muscle - Skeletal*RP3--337O18.9*−0.20.000028Adipose - Subcutaneous*NEURL2*−0.220.000036Lung*NEURL2*−0.220.000073ThyroidTable 5The sQTL values of the 3 SNPs of the *MMP* genes. (according to Genotype-Tissue Expression (GTEx) (<http://www.gtexportal.org/>)).Table 5ChrSNPReference alleleAlternative alleleGene SymbolIntron IdEffect Size (β)P-ValueTissue11rs1799750TCT*WTAPP1*102,832,906:102,833,452:clu_16,168−0.510.000000000065Testis20rs3918242CT*CD40*46,126,741:46,128,138:clu_33,0450.50.0000000029Thyroid*CD40*46,126,741:46,128,138:clu_32,5080.450.0000000067Lung*CD40*46,126,741:46,128,138:clu_32,5080.450.0000000067Lung*SLC12A5*46,021,886:46,023,369:clu_29,5290.790.0000000098Pituitary*CD40*46,126,741:46,128,138:clu_27,4420.490.00000041Artery - Aorta*ACOT8*45,841,956:45,844,263:clu_24,5400.580.0000011Heart - Left Ventricle*CD40*46,126,741:46,128,138:clu_22,0550.740.0000015Cells - EBV-transformed lymphocytes*ACOT8*45,841,956:45,844,263:clu_27,1230.490.0000041Heart - Atrial Appendage20rs17576AG*SLC12A5*46,021,886:46,023,369:clu_29,5290.630.0000000000093Pituitary*SLC12A5*46,023,071:46,023,369:clu_24,852−0.450.00000033Brain - Cortex*SLC12A5*46,021,886:46,023,369:clu_26,6480.460.000002Brain - Cerebellum*SLC12A5*46,021,886:46,023,369:clu_53,3530.380.000011Testis

2. Experimental design, materials, and methods {#sec0002}
==============================================

2.1. Study subjects {#sec0003}
-------------------

The study cohort consisted of 1556 Russian participants, including 536 patients diagnosed with POAG (290 females and 246 males), 621 patients with EH (359 females and 262 males), and 399 patients with PU (211 females and 188 males). The study participants were clinically examined at the Department of Eye Microsurgery (patients with POAG), Department of Cardiology (patients with EH), and Department of Gastroenterology (patients with PU) of St. Iasaf Belgorod Regional Clinical Hospital. All participants were self-reported unrelated Russians born in Central Russia [@bib0046]. The study was approved by the Regional Ethics Committee of Belgorod State University. All participants signed an informed consent prior to the enrolment to this study.

2.2. DNA analysis {#sec0004}
-----------------

Phlebotomy was performed by a certified nurse. Blood (5 ml) was drawn from the ulnar vein to a plastic vial (Vacutainer^Ⓡ^) with 0.5 M EDTA (рН = 8.0). Total genomic DNA was isolated from the buffy coat by the standard phenol-chloroform protocol [@bib0047] and then checked for quality using Nanodrop 2000 spectrophotometer (Thermo Scientific, Inc.). Only samples with А260/А280 = 1.7--2.0 were used for the analysis. The isolated DNA was stored at −80°С.

Three SNPs of the *MMP* genes (rs1799750 *MMP1*, rs3918242 and rs17576 *MMP9*) were selected for the analysis. The following selection criteria were applied \[[@bib0048],[@bib0049]\]: 1) Previously reported associations with POAG, EH and PU ([Table 2](#tbl0002){ref-type="table"}), 2) Regulatory potential (regSNP) ([Table 3](#tbl0003){ref-type="table"}), 3) Effect on gene expression (eSNP) ([Table 4](#tbl0004){ref-type="table"}), 4) Splicing QTLs (sSNP) ([Table 5](#tbl0005){ref-type="table"}), and 5) MAF \> 5%.

The selected loci were associated with POAG, EH and PU in previously published candidate gene association studies ([Table 2](#tbl0002){ref-type="table"}) and have functional significance: significant regulatory potential ([Table 3](#tbl0003){ref-type="table"}) (determined using the online tools HaploReg, v4.1 update 05.11.2015, <https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>), influence gene expression level ([Table 4](#tbl0004){ref-type="table"}) and involved in splicing QTLs ([Table 5](#tbl0005){ref-type="table"}) (determined using the GTExportal data, <http://www.gtexportal.org/>).

The DNA samples used for the analysis had concentration 10--15 ng/ml. A single well iPLEX SNP genotyping assay was designed using the Assay Design Suite 1.0 (<http://agenabio.com/assay-design-suite-10-software>). For this purpose, three SNPs of interest were retrieved from dbSNP of NCBI and imported into the software according to their IDs. DNA genotyping was performed on the MALDI‐TOF mass spectrometry iPLEX platform (Agena Bioscience Inc, San Diego, CA).

For quality control of genotyping, 5% of blind replicate samples were included. The concordance for replicate samples was 100%.

2.3. Statistical analysis {#sec0005}
-------------------------

The studied SNPs were checked for their correspondence to the Hardy-Weinberg equilibrium (HWE) using the chi-square test. The frequencies of alleles and genotypes were analyzed for possible differences between the females and males in the study sample using the Kruskall-Wallis test.
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Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dib.2020.106004](https://doi.org/10.1016/j.dib.2020.106004){#interref0008}.

[^1]: Abbreviations: POAG - primary open-angle glaucoma, EH - essential hypertension, PU - peptic ulcer.

[^2]: Abbreviations: POAG - primary open-angle glaucoma, EH - essential hypertension, IS - ischemic stroke, PU - peptic ulcer.
